Actuate Therapeutics Inc Financials
This page shows Actuate Therapeutics Inc (ACTU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Actuate’s business still runs on cash burn, while share issuance and financing inflows are what strengthened the latest balance sheet.
Financing inflows of$23.7M were larger than the operating cash burn of$19.2M , so cash and liquidity improved even though the underlying operation still consumed cash at a heavy rate. That reliance on outside funding, rather than internal cash generation, is what allowed equity to rebuild to$7.9M and made the balance sheet materially less strained.
Net loss and cash burn moved together: a net loss of
Share count moved from 19.5M shares to 23.2M shares, reinforcing that outside capital rather than operations funded the business. R&D fell to
Financial Health Signals
Actuate Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Actuate Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Actuate Therapeutics Inc reported a net loss of $22.2M while operations used $19.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Actuate Therapeutics Inc reported an operating loss of $22.5M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Actuate Therapeutics Inc reported -$22.2M in net income in fiscal year 2025. This represents an increase of 18.5% from the prior year.
Actuate Therapeutics Inc earned -$1.06 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Actuate Therapeutics Inc held $13.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Actuate Therapeutics Inc's ROE was -280.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25908.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Actuate Therapeutics Inc invested $10.3M in research and development in fiscal year 2025. This represents a decrease of 44.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ACTU Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| R&D Expenses | N/A | $10.3M-44.9% | $18.7M | N/A |
| SG&A Expenses | N/A | $12.2M+88.2% | $6.5M+98.6% | $3.3M |
| Operating Income | N/A | -$22.5M+10.6% | -$25.2M | N/A |
| Interest Expense | N/A | $20K+8.2% | $19K-57.1% | $44K |
| Income Tax | N/A | $8000.0% | $800 | $0 |
| Net Income | N/A | -$22.2M+18.5% | -$27.3M | N/A |
| EPS (Diluted) | — | -$1.06 | -$3.26 | -$17.24 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACTU Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $14.0M+50.6% | $9.3M+211.1% | $3.0M |
| Current Assets | $13.6M+48.2% | $9.2M+207.4% | $3.0M |
| Cash & Equivalents | $13.2M+52.3% | $8.6M+192.1% | $3.0M |
| Total Liabilities | $6.1M-33.7% | $9.2M-91.0% | $102.6M |
| Current Liabilities | $5.7M-35.2% | $8.8M+27.2% | $6.9M |
| Total Equity | $7.9M+7505.6% | $104K+100.1% | -$99.6M |
| Retained Earnings | -$154.6M-16.8% | -$132.4M-26.0% | -$105.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ACTU Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$19.8M | -$19.2M+12.1% | -$21.8M | N/A |
| Financing Cash Flow | $17.8M | $23.7M-13.8% | $27.5M+565.8% | $4.1M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACTU Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Return on Equity | -280.5%+25908.5pp | -26189.0% | N/A |
| Return on Assets | -158.4%+134.5pp | -292.8% | N/A |
| Current Ratio | 2.39+1.3x | 1.05+0.6x | 0.43 |
| Debt-to-Equity | 0.77-87.7x | 88.44 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Actuate Therapeutics Inc Ranks
Frequently Asked Questions
Is Actuate Therapeutics Inc profitable?
No, Actuate Therapeutics Inc (ACTU) reported a net income of -$22.2M in fiscal year 2025.
What is Actuate Therapeutics Inc's return on equity (ROE)?
Actuate Therapeutics Inc (ACTU) has a return on equity of -280.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Actuate Therapeutics Inc's operating cash flow?
Actuate Therapeutics Inc (ACTU) recorded an outflow of $19.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Actuate Therapeutics Inc's total assets?
Actuate Therapeutics Inc (ACTU) had $14.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Actuate Therapeutics Inc spend on research and development?
Actuate Therapeutics Inc (ACTU) invested $10.3M in research and development during fiscal year 2025.
What is Actuate Therapeutics Inc's current ratio?
Actuate Therapeutics Inc (ACTU) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.
What is Actuate Therapeutics Inc's debt-to-equity ratio?
Actuate Therapeutics Inc (ACTU) had a debt-to-equity ratio of 0.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Actuate Therapeutics Inc's return on assets (ROA)?
Actuate Therapeutics Inc (ACTU) had a return on assets of -158.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Actuate Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Actuate Therapeutics Inc (ACTU) had $13.2M in cash against an annual operating cash burn of $19.2M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Actuate Therapeutics Inc's Piotroski F-Score?
Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Actuate Therapeutics Inc's earnings high quality?
Actuate Therapeutics Inc (ACTU) reported a net loss of $22.2M while operations used $19.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Actuate Therapeutics Inc cover its interest payments?
Actuate Therapeutics Inc (ACTU) reported an operating loss of $22.5M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.